alpha-Fetoproteins

"alpha-Fetoproteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.

Descriptor ID	D000509
MeSH Number(s)	D12.776.124.790.106.092 D12.776.320.525.500 D12.776.377.228.500 D12.776.377.715.085.092 D23.101.140.050
Concept/Terms	alpha-Fetoproteins alpha-Fetoproteins alpha Fetoproteins alpha-Fetoprotein alpha Fetoprotein

Below are MeSH descriptors whose meaning is more general than "alpha-Fetoproteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Alpha-Globulins [D12.776.124.790.106]
alpha-Fetoproteins [D12.776.124.790.106.092]
Fetal Proteins [D12.776.320]
Fetal Globulins [D12.776.320.525]
alpha-Fetoproteins [D12.776.320.525.500]
Globulins [D12.776.377]
Fetal Globulins [D12.776.377.228]
alpha-Fetoproteins [D12.776.377.228.500]
Serum Globulins [D12.776.377.715]
Alpha-Globulins [D12.776.377.715.085]
alpha-Fetoproteins [D12.776.377.715.085.092]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
alpha-Fetoproteins [D23.101.140.050]

Below are MeSH descriptors whose meaning is related to "alpha-Fetoproteins".

Below are MeSH descriptors whose meaning is more specific than "alpha-Fetoproteins".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "alpha-Fetoproteins" by people in this website by year, and whether "alpha-Fetoproteins" was a major or minor topic of these publications.

Bar chart showing 19 publications over 13 distinct years, with a maximum of 3 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2003	0	1	1
2005	0	1	1
2011	1	0	1
2013	0	1	1
2014	0	1	1
2015	0	1	1
2017	0	2	2
2019	1	0	1
2020	1	1	2
2021	0	2	2
2022	2	1	3
2023	0	2	2

Below are the most recent publications written about "alpha-Fetoproteins" by people in Profiles.

Gil LA, Knaus ME, Stanek JR, Srivatsa S, Patterson KN, Wood RJ, Minneci PC, Ranalli MA, Aldrink JH. Variability in Surveillance Strategies Following Resection of Sacrococcygeal Teratoma. J Surg Res. 2024 Mar; 295:423-430.

View in: PubMed
Lin SY, Xia W, Kim AK, Chen D, Schleyer S, Choi L, Wang Z, Hamilton JP, Luu H, Hann HW, Chang TT, Hu CT, Woodard A, Gade TP, Su YH. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma. Sci Rep. 2023 12 07; 13(1):21585.

View in: PubMed
Gulersen M, Krantz D, Li X, Peyser A, Goldman R, Mullin C, Bornstein E, Rochelson B. The impact of preimplantation genetic testing on first- and second-trimester maternal serum analyte levels. J Matern Fetal Neonatal Med. 2022 Dec; 35(26):10435-10443.

View in: PubMed
Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hann HW. Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. Viruses. 2022 04 08; 14(4).

View in: PubMed
Kim AK, Hamilton JP, Lin SY, Chang TT, Hann HW, Hu CT, Lou Y, Lin YJ, Gade TP, Park G, Luu H, Lee TJ, Wang J, Chen D, Goggins MG, Jain S, Song W, Su YH. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. 2022 06; 126(10):1432-1438.

View in: PubMed
Araganji R, Somannavar MS, Vernekar SS, Kavi A, Hoffman MK, Goudar SS. The impact of low-dose aspirin on markers of inflammation and placental function: an ancillary study of the ASPIRIN trial. J Matern Fetal Neonatal Med. 2022 Dec; 35(25):6901-6905.

View in: PubMed
Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med. 2021 05; 10(9):3059-3067.

View in: PubMed
Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020 09 15; 26(18):4795-4804.

View in: PubMed
Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-?RI inhibitor galunisertib. PLoS One. 2020; 15(3):e0222259.

View in: PubMed
Lawrence AE, Fallat ME, Hewitt G, Hertweck P, Onwuka A, Afrazi A, Bence C, Burns RC, Corkum KS, Dillon PA, Ehrlich PF, Fraser JD, Gonzalez DO, Grabowski JE, Kabre R, Lal DR, Landman MP, Leys CM, Mak GZ, Overman RE, Rademacher BL, Raiji MT, Sato TT, Scannell M, Sujka JA, Wright T, Minneci PC, Deans KJ, Aldrink JH. Understanding the Value of Tumor Markers in Pediatric Ovarian Neoplasms. J Pediatr Surg. 2020 Jan; 55(1):122-125.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement